- Policy
- Quick diagnosis is essential for Hepatitis C
- by Nov 18, 2022 06:03am
- Pharmaceutical companies such as BMS, Gilead, and Abbvie introduced direct anti-virus (DAA) treatments, and hepatitis C opened the era of complete recovery. Re-treatment options for a small number of patients who failed to treat also appeared this year. The goal of hepatitis C is to find "hidden patients" who have not yet been diagnosed. Expe
- Policy
- Budget increase for drugs and vaccines under NA review
- by Lee, Jeong-Hwan Nov 17, 2022 05:54am
- The proposal to set a new budget worth KRW 14.4 billion to support the patients’ medical expenses of ultra-high-priced new drugs for rare diseases will be reviewed by the Adjustment Subcommittee of the National Assembly’s Special Committee on Budget and Accounts. A plan to increase the budget for the K-global vaccine fund project by KRW
- Opinion
- [Reporter's view] Generic drugs can't be me-too drug
- by Kim, Jin-Gu Nov 17, 2022 05:54am
- Controversy is brewing over the government's push to replace the term "generic" with me-too-drug. The KPBMA and the Korean Pharmaceutical Association immediately objected. They stress that it is not enough to contain all the meanings of the term generic in the term copy drug. The backlash from the pharmaceutical industry seems reasonable. Thi
- InterView
- “Amgen addresses all unmet needs regardless of indication”
- by Eo, Yun-Ho Nov 17, 2022 05:54am
- Amgen owns a vast portfolio of treatments in many areas. Rather than focusing on a particular field, the company has been known to release new drugs in the right places at the right time In addition to actively developing drugs for chronic diseases such as the osteoporosis treatments 'Prolia (denosumab)’ and ‘Evenity (romosozumab),’ t
- Company
- Generic companies won 9 out of 10 patent disputes
- by Kim, Jin-Gu Nov 17, 2022 05:54am
- In a patent dispute between the original company and the generic company over generic for exclusivity, a study found that the generic company's first trial winning rate reached 88.5%. Lee Myung-hee, a senior researcher at the KIIP, announced the results of the impact assessment of the licensing patent-linked system at the 2022 Pharmaceutic
- Company
- Announcement of commercialization of oral insulin
- by Eo, Yun-Ho Nov 17, 2022 05:54am
- Expectations are rising for PO use for injectable insulin. Medicox recently signed an exclusive distribution contract with Israeli pharmaceutical company Oramed Pharmaceuticals following the introduction of oral insulin technology. As a result, Medicox will be able to distribute Oramed's oral insulin candidate "ORMD-0801" for 10 years in Kore
- Company
- The aftermath of stricter generic regulations?
- by Kim, Jin-Gu Nov 16, 2022 06:11am
- It was found that the number of applications for generic for exclusivity decreased sharply. Experts agree that the implementation of the 1+3 system has affected the decrease in the number of generic for exclusivity applications. Lee Myung-hee, a senior researcher at KIIP, introduced the number of generic for exclusivity applications in 2020 a
- Company
- Gavreto applies for reimbursement following Retevmo
- by Eo, Yun-Ho Nov 16, 2022 06:10am
- In line with the progress made in Retevmo’s reimbursement review process, its competitor Gavreto was also found to have started its reimbursement process in Korea. According to industry sources, Roche Korea submitted an application for the reimbursement of its RET (Rearranged during transfection) gene fusion targeted therapy Gavreto (pr
- Policy
- Use of Evusheld extended to the severely immunocompromised
- by Kim, Jung-Ju Nov 16, 2022 06:10am
- The COVID-19 Vaccination Response Promotion Team (Head: KDCA Commissioner Kyung-Ran Baek) announced that it had expanded the eligibility of Evusheld as of the 14th to protect the severely immunocompromised from the next wave of COVID-19 outbreak that may arise in the winter season. With the expansion, blood cancer patients, transplant rec
- Company
- Impinzi's indication of biliary tract cancer
- by Nov 16, 2022 06:10am
- AstraZeneca Korea announced on the 14th that its immune anticancer drug "Imfinzi" has received additional approval from the Ministry of Food and Drug Safety for biliary tract cancer. Imfinzi can be used as a combination therapy with Gemcitabine and Cisplatin in the primary treatment of patients with locally advanced or metastatic biliary t
